Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00830154 | A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering | PHASE2 | COMPLETED | 321 | — | — | Feb 1, 2009 | Jan 1, 2011 | Aug 28, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 0.30 mg pagoclone BID |
| 2 | EXPERIMENTAL | 0.60 mg pagoclone BID |
| 3 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| pagoclone | DRUG | 0.30 mg BID, 0.60 mg BID |
| placebo | OTHER | placebo |
Inclusion Criteria: * Male and females age 18 to 80 years presenting with a history of stuttering with onset prior to age 8 years old. * Stuttering severity must be notable for \> 3 syllables stuttered on a reading and cenversational task at scereening and with at least 2% contributed individually ...